Unmet needs in late-onset genetic cholestasis: an expert discussion
This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).
Trial summaries from the AASLD Liver Meeting 2024
Stay up to date with the latest in Primary Biliary Cholangitis with downloadable summaries of key trials from the 2024 AASLD Liver Meeting.
Deepak Joshi
Silvia Vilarinho
Emma Culver
Comprehensive PBC management: innovative and personalized plans to enhance patient outcomes
Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.
IBAT trial updates confirm efficacy and safety for PFIC patients
Further findings on the efficacy and safety of ileal bile acid transporter inhibitors for patients with progressive familial intrahepatic cholestasis have been presented at the 2024 AASLD The Liver Meeting in San Diego, California, USA.
Whole-exome sequencing aids adult-onset cholestatic liver disease diagnosis
Dr Miki Scaravaglio talks through her proof-of-principle study findings for use of whole-exome sequencing to aid the diagnosis of people with adult-onset cholestatic liver disease.
Whole-exome sequencing sheds light on unexplained adult-onset cholestatic liver disease
Whole-exome sequencing led to definitive diagnoses for almost a quarter of patients with unexplained adult-onset cholestatic liver disease, say Italian researchers.
ABCB11 alteration linked to anabolic steroid-induced liver injury susceptibility
Dr Andrew Stolz reports on the relationship between alterations to the ABCB11 gene and the risk of drug-induced liver injury from anabolic steroids.
PFIC trial updates continue to support IBAT inhibitor efficacy and safety
Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.
ABCB11 variants increase susceptibility to anabolic steroid-induced liver injury
Alterations to ABCB11 play a “pivotal role” in the development of drug-induced liver injury from anabolic steroids, US researchers reported at the 2024 AASLD The Liver Meeting in San Diego, California, USA.
Oral contraceptive absorption unhindered by odevixibat in healthy women
Trial findings suggest that the IBAT inhibitor odevixibat does not prevent absorption of combined oral contraceptives in healthy women.
EASL guidelines direct genetic cholestatic liver management
An EASL expert panel has developed clinical practice guidelines for the management of progressive familial intrahepatic cholestasis and other genetic cholestatic liver diseases.
Verena Keitel-Anselmino
Richard Thompson
Dr Adriaan Van der Meer
Dr Mark Swain
Dr Marco Carbone
Mo Christie
Dr Palak Trivedi
Dr Gideon Hirschfield
Professor David Jones
Dr Marlyn Mayo
Dr Andreas Kremer
Dr Kris Kowdley
Navigating Challenges in PBC Management: Focus on Inadequate Responders and Symptomatic Itching
In this case study module, Marlyn Mayo discusses 3 short patient profiles to illustrate difficult situations when treating patients with PBC including managing inadequate response to initial therapy and symptomatic itching.
Breaking down PBC: a comprehensive guide
Led by Kris Kowdley, this interactive, comprehensive guide to Primary Biliary Cholangitis (PBC) provides details on the pathogenesis, diagnosis, management and latest clinical data for PBC. Click through the sections, or download the PDF to use as a guide in your clinic.
PBC Clinical insights: evaluating therapeutic response and disease management
CME case study for the identification and management of Primary Biliary Cholangitis (PBC) including therapy response and disease management, for a 42 year old with abnormal liver blood test results.
Coping with PBC: treatment challenges and QoL insights
Kris Kowdley meets with patient Sabrina Reeser as they discuss the patient experience of treatment for PBC, including treatment challenges, variability in doctor-patient communication and involvement in clinical trials.
Combination therapies and real world treatment for PBC patients
Dr Adriaan Van der Meer shares his insights on the results from the combination trial of obeticholic acid and bezafibrate for PBC patients, presented at EASL 2024 in Milan, Italy. In addition, discover key findings and learn about the RECAPITULATE trial, focusing on real-world treatment outcomes.
Breaking analysis of ASSURE from EASL 2024
Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.
ELATIVE updates from EASL 2024
Professor Marco Carbone reviews the latest updates from the ELATIVE trial of elafibranor, presented at EASL 2024 in Milan, Italy. Discover key insights on efficacy, quality of life improvements, and the broader significance of these results.
‘Rapid and durable response’ with seladelpar in patients with PBC and cirrhosis
ASSURE study findings show that seladelapr elicits a biochemical response in patients with primary biliary cholangitis and cirrhosis.
Biochemical response benefits with elafibranor are ‘consistent’ for PBC
ELATIVE subanalysis confirms improved biochemical response with elafibranor over placebo for primary biliary cholangitis according to various different criteria.
Adding obeticholic acid to slow-release bezafibrate shows promise for PBC
Combining slow-release bezafibrate with obeticholic acid shows treatment potential for patients with primary biliary cholangitis.
ELATIVE trial shows pruritus benefits with elafibranor in PBC
ELATIVE trial results for pruritus show benefits for both severity and impact on the quality of life of patients with primary biliary cholangitis.
Walking the path of PBC: navigating symptoms and QoL
David Jones meets with patient and patient advocate Mo Christie as they discuss the patient experience for PBC, including the burden of the disease and its impact on quality of life, with special reference to the common, and commonly misunderstood symptom, itch.
The evolving landscape of PBC: new therapies and future directions
Kris Kowdley and David Jones share their insights on the evolving landscape of PBC, including new and upcoming therapy options, and how these may change practice for the disease.
Barriers and symptoms burden: the unmet needs in PBC
Drs Marlyn Mayo and Gideon Hirschfield discuss the unmet needs in PBC management, highlighting the significant burden that symptoms pose for patients, the importance of monitoring and a patient-centric management approach offering insights into what might lie ahead in 2024.
The Liver Meeting 2023 – updates to the current landscape
Dr Palak Trivedi joins Dr Gideon Hirschfield to explore pivotal insights from The Liver Meeting 2023. Together, they highlight crucial updates, unveil novel findings, and deliver a concise overview of the current landscape of PBC.
Andreas Kremer discusses advances in second-line obeticholic acid
Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.
Kris Kowdley’s analysis of breakthrough research on PBC
Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.
Gideon Hirschfield highlights noteworthy findings on PBC
Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.
Complete biochemical and POISE response seen with second-line OCA in real-world setting
Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.
ELATIVE: Elafibranor shows treatment efficacy in patients with PBC
ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.
Positive RESPONSE for seladelpar in patients with PBC
RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.
Denosumab performs well against bisphosphonate for PBC-related osteoporosis
Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.
Adding bezafibrate to OCA shows treatment promise for PBC
Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.
